Latigo Biotherapeutics is like Beyond Meat for pain relief, developing innovative, non-addictive alternatives to replace the problematic reliance on opioids.

Latigo Biotherapeutics is like Tesla for pain management, building a pipeline of advanced, non-addictive solutions to replace the outdated and problematic (opioid-reliant) standard of care.

• LTG-001: An oral Nav1.8 inhibitor currently in Phase 3 development for fast-acting, opioid-sparing relief of moderate to severe acute pain, including postoperative pain, and also being advanced as an intravenous (IV) formulation.
• LTG-321: A next-generation oral Nav1.8 inhibitor in Phase 2 for chronic musculoskeletal pain, with initial development focused on osteoarthritis (OA).
• LTG-418: An earlier-stage, next-generation Nav1.8 inhibitor predicted to have a lower dose, enabling a broader range of formulations and routes of administration for acute and chronic pain.
• Additional Ion Channel Modulators: Candidates in discovery targeting other ion channels involved in peripheral pain transmission, offering complementary mechanisms to Nav1.8 inhibition.

Latigo Biotherapeutics (LTGO) is a clinical-stage biopharmaceutical company focused on developing innovative non-opioid pain medicines. As a company in the development phase, with its lead product candidates (LTG-001, LTG-321, LTG-418) still undergoing clinical trials and seeking regulatory approval, Latigo Biotherapeutics does not currently have commercialized products on the market.

Therefore, Latigo Biotherapeutics does not have major customers in the traditional sense of selling products or services to other companies or individuals at this time. Its primary activities revolve around research, development, and clinical trials aimed at bringing its drug candidates to market in the future.

Nima Farzan Chief Executive Officer

Nima Farzan was appointed CEO in July 2024. He brings over two decades of leadership experience in the biopharmaceutical industry. Previously, he served as CEO of Kinnate Biopharma Inc., which was acquired by Xoma Corp. During his tenure at Kinnate, which he joined in 2020, he built the organization and advanced three precision oncology compounds into clinical development. Latigo Biotherapeutics itself was incubated by Westlake Village BioPartners, which also led its Series A financing, alongside co-leads 5AM Ventures and Foresite Capital.

Neha Krishnamohan Chief Financial Officer and Chief Business Officer

Neha Krishnamohan was appointed CFO and CBO in March 2026. She has more than 15 years of experience in healthcare investment banking, corporate finance, and strategic leadership. Prior to Latigo, Ms. Krishnamohan was CFO and Executive Vice President of Corporate Development at Artiva Biotherapeutics, Inc., where she oversaw financial operations, business development, and investor relations, including the company's transition to a public company and a $179 million initial public offering. Before Artiva, she held the same roles at Kinnate Biopharma, where she played a key role in the company's strategic alternatives, leading to an asset sale to Pierre Fabre Laboratories and the sale of Kinnate to XOMA Corporation. She also previously worked as a Vice President in the Healthcare Investment Banking Group and Mergers and Acquisitions Group at Goldman Sachs.

Neil Singla, M.D. Chief Medical Officer

Neil Singla is the chief medical officer of Latigo Biotherapeutics. He is also the founder and former chief executive officer of Lotus Clinical Research.

Julia Chapman Senior Vice President, Operations

Julia Chapman serves as the Senior Vice President of Operations at Latigo Biotherapeutics. She possesses over 15 years of experience in public and private biopharmaceutical companies, with expertise in advancing complex therapeutic programs from discovery to commercialization. Her prior leadership roles include positions in corporate strategy, program management, and business development at companies such as Novartis, BridgeBio, Verve, and Precision Biosciences. She has managed strategic planning for major franchises and pipelines and supported significant partnerships.

Bryan Moyer, Ph. D. Senior Vice President, Discovery

Bryan Moyer is the Senior Vice President, Discovery at Latigo Biotherapeutics.

1. Clinical Trial Failure and Regulatory Approval Risk: Latigo Biotherapeutics is a clinical-stage company whose success is heavily dependent on the successful completion of its ongoing and planned clinical trials and subsequent regulatory approvals. The company plans to initiate a placebo-controlled Phase 3 trial for LTG-001 in bunionectomy and an open-label Phase 3 safety trial in the second half of 2026, with topline results expected in the second half of 2027. Similarly, its next-generation candidate, LTG-321, is currently in a Phase 2 proof-of-concept trial with topline results also expected in the second half of 2027. Failure to meet primary or key secondary endpoints in these trials, encountering unforeseen safety or tolerability issues, or experiencing delays in regulatory review or approval would significantly jeopardize the development and commercialization of its product candidates, thereby posing a substantial risk to the business.
2. Competition and Market Differentiation Risk: The pain management market is highly competitive, and a direct competitor, suzetrigine (Journavx), a first-in-class Nav1.8 inhibitor, received FDA approval in January 2025. While this approval provides a regulatory precedent for the therapeutic class, it also establishes an entrenched competitor. Although Latigo Biotherapeutics believes suzetrigine is limited by efficacy, slow onset, and contraindications, Latigo's product candidates, LTG-001 and LTG-321, must demonstrate clear and compelling advantages in terms of efficacy, speed of onset, safety, or tolerability to capture significant market share. If Latigo's products are not perceived as sufficiently differentiated or superior to Journavx or other existing pain treatments, including opioids and NSAIDs, their commercial uptake and overall market success could be severely limited.

The FDA approval and market launch of suzetrigine (Journavx), the first-in-class Nav1.8 inhibitor, poses a clear emerging threat. As an already approved non-opioid, non-addictive selective pain signal inhibitor for Nav1.8, suzetrigine directly competes with Latigo Biotherapeutics' pipeline by establishing a first-mover advantage in their shared therapeutic mechanism and target market, despite LTGO's view of its limitations.

Latigo Biotherapeutics (LTGO) targets significant addressable markets in the United States for its pain therapeutics:

• For acute musculoskeletal pain, the market encompasses approximately 80 million adults who received prescriptions in 2022.
• For chronic musculoskeletal pain, including conditions like osteoarthritis (OA) and Chronic Lower Back Pain, more than 60 million Americans were affected in 2023.
• For peripheral neuropathic pain, approximately 10 million patients were prescribed medicine in 2022.

Latigo Biotherapeutics (LTGO) anticipates several key drivers for future revenue growth over the next two to three years, primarily stemming from the advancement and potential commercialization of its pipeline of non-opioid pain medicines:

1. Potential FDA Approval and Commercialization of LTG-001 for Acute Pain: The company's lead product candidate, LTG-001, an oral Nav1.8 inhibitor, is in advanced clinical development for moderate to severe acute pain, including postoperative pain. Following positive data from an abdominoplasty trial, Latigo plans to initiate a Phase 3 bunionectomy trial and an open-label Phase 3 safety trial in the second half of 2026, with topline results expected in the second half of 2027. Successful completion of these trials and subsequent regulatory approval would position LTG-001 to address a significant unmet need in a high-volume market currently dominated by opioids.
2. Expansion of LTG-001 into Intravenous (IV) Formulation: Beyond oral dosing, LTG-001 is being developed as a potential intravenous formulation. This IV option would support its use in hospital settings and facilitate a seamless transition from inpatient postoperative care to outpatient pain management, thereby expanding the addressable market and utility of the lead candidate.
3. Advancement of LTG-321 for Chronic Musculoskeletal Pain: LTG-321, a next-generation Nav1.8 inhibitor, is being developed for chronic musculoskeletal pain, starting with osteoarthritis (OA). The company has initiated a Phase 2 proof-of-concept trial in patients with OA of the knee, with topline results anticipated in the second half of 2027. Positive outcomes from this trial would validate LTG-321's potential in the chronic pain market, representing a significant new product opportunity.
4. Progression of Earlier-Stage Pipeline Candidates: Latigo is also advancing LTG-418, another next-generation Nav1.8 inhibitor predicted to have a substantially lower effective dose, potentially enabling diverse formulations like gels, patches, and injectables. Additionally, the company is engaged in the discovery of other ion channel modulators for various pain etiologies, including neuropathic pain. Progress in these earlier-stage programs will diversify Latigo's pipeline and offer multiple avenues for long-term revenue generation.